dr. yardley discusses enzalutamide in hr breast cancer
Published 6 years ago • 126 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
2:10
dr. yardley on enzalutamide plus exemestane in hormone-positive breast cancer
-
1:26
dr. yardley on challenges with resistance mechanisms in hr /her2- breast cancer
-
2:15
dr. yardley discusses cdk4/6 inhibitors for breast cancer
-
1:59
the role of enzalutamide in hr advanced breast cancer
-
1:58
dr. yardley on endocrine therapy plus cdk4/6 inhibitors in breast cancer with visceral metastases
-
0:56
dr. yardley on unmet need for patients with her2 breast cancer
-
1:35
dr. yardley on therapy considerations in patients with advanced breast cancer/visceral metastases
-
1:18
dr. yardley on the utility of cdk4/6 inhibitors in metastatic hr breast cancer
-
1:50
dr. yardley discusses data with talazoparib in breast cancer
-
2:01
dr. yardley on the respect trial in her2-positive breast cancer
-
1:24
dr. yardley on emerging agents in her2-positive breast cancer
-
2:27
dr. yardley on the aphinity trial for her2-positive breast cancer
-
0:43
dr. yardley on the role of biosimilars in breast cancer
-
2:19
dr. yardley on importance of tailoring treatment to breast cancer subtypes
-
2:11
dr. yardley discusses an expanded access study of t-dm1 in breast cancer
-
2:03
dr. yardley on tnacity trial for triple-negative breast cancer
-
1:42
enzalutamide shows promise in hr breast cancer
-
2:07
dr. yardley on the d-care trial in women with high-risk early breast cancer
-
2:39
dr. yardley on current recommendations for er breast cancer treatment